Novawax Company One of the US biopharmaceutical manufacturers and the Indian Serum Institute (SII), which is a partner Together submit documents to the World Health Organization (WHO) for emergency approval. Vaccines against COVID-19
By Stanley Erk, President and CEO of Novavax Novavax said on Twitter that the WHO’s application for emergency registration is an important step to accelerate the spread of the vaccine to countries. all over the world wanting
The Novavax vaccine, officially NVX-CoV2373, is a subunit protein vaccine. It was 90.4% effective in preventing overall moderate-to-severe morbidity in the Phase 3 test.
The preliminary information is the Novavax vaccine. 89.7% protection against alpha coronavirus (UK), 55% protection against beta coronavirus (South Africa), while Delta strain (India) is still being studied. that has not yet been concluded
The filing for the Novavax vaccine is slightly later than originally scheduled. After Novawax It previously announced that it plans to file within August. but had to be postponed to the end of September instead
Novavax Vaccine Company and SIA has submitted an application for registration of a vaccine against COVID-19 already in at least 3 countries in Asia: India, Indonesia and the Philippines. which is in accordance with the objectives of the company They want developing and poor countries to have access to vaccines first.